NCT06773377

Brief Summary

  1. 1.Study the expression of CD44 in various histopathological types of RCC.
  2. 2.Study the association between CD44 expression and other clinicopathological parameters
  3. 3.study the impact of CD44 expressions in tumor and patients' survival

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
77

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Nov 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress48%
Nov 2025Dec 2026

First Submitted

Initial submission to the registry

January 9, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 14, 2025

Completed
10 months until next milestone

Study Start

First participant enrolled

November 1, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

January 14, 2025

Status Verified

January 1, 2025

Enrollment Period

1 year

First QC Date

January 9, 2025

Last Update Submit

January 9, 2025

Conditions

Renal Cell Cancer

Outcome Measures

Primary Outcomes (1)

  • Study of the prognostic impact of CD44 on renal cell carcinoma.

    assess the expression of CD44 in various histopathological types of RCC. understanding their biology is mandatory to define novel potential prognostic and therapeutic targets for all RCC subtypes.

    Baseline

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with RCC who had undergone radical or partial nephrectomy, between 2014 and 2019.

You may qualify if:

  • patient must be more than 18 years
  • Patients with complete pathological data

You may not qualify if:

  • The presence of any other organ malignancies
  • Patients who lost follow-up after nephrectomy less than 3-year,
  • Patients with incomplete pathological data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Carcinoma, Renal Cell

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Central Study Contacts

Wafaa Ashraf Fawzy, Doctor

CONTACT

+201067857964wafaaashraf583@gmail.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

January 9, 2025

First Posted

January 14, 2025

Study Start

November 1, 2025

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

January 14, 2025

Record last verified: 2025-01